Lake Street Capital Raises BioScrip (BIOS) Price Target to $10.00

BioScrip (NASDAQ:BIOS) had its price objective raised by Lake Street Capital from $4.50 to $10.00 in a research report released on Friday morning, The Fly reports. The brokerage currently has a buy rating on the stock.

BIOS has been the topic of a number of other reports. BidaskClub lowered BioScrip from a strong-buy rating to a buy rating in a report on Saturday, October 6th. TheStreet raised BioScrip from a d+ rating to a c- rating in a report on Monday, November 26th. Barrington Research reaffirmed a buy rating and set a $4.00 target price on shares of BioScrip in a report on Friday, October 5th. Finally, Zacks Investment Research raised BioScrip from a sell rating to a hold rating in a report on Tuesday, October 9th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $4.85.

Shares of BIOS stock traded up $0.11 during mid-day trading on Friday, reaching $3.88. The stock had a trading volume of 1,911,910 shares, compared to its average volume of 1,151,152. The firm has a market capitalization of $482.71 million, a PE ratio of -8.82 and a beta of 0.55. BioScrip has a 1-year low of $2.31 and a 1-year high of $4.13.

BioScrip (NASDAQ:BIOS) last announced its quarterly earnings data on Tuesday, November 6th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.02). The firm had revenue of $181.00 million during the quarter, compared to analyst estimates of $171.35 million. The business’s revenue for the quarter was down 8.9% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.12) earnings per share. On average, equities analysts expect that BioScrip will post -0.33 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of BIOS. Rothschild Asset Management Inc. acquired a new stake in BioScrip during the second quarter worth about $3,486,000. Rothschild & Co. Asset Management US Inc. grew its holdings in BioScrip by 82.8% during the third quarter. Rothschild & Co. Asset Management US Inc. now owns 2,174,826 shares of the company’s stock worth $6,742,000 after acquiring an additional 985,235 shares during the period. BlackRock Inc. grew its holdings in BioScrip by 14.6% during the second quarter. BlackRock Inc. now owns 7,584,345 shares of the company’s stock worth $22,222,000 after acquiring an additional 967,219 shares during the period. Dimensional Fund Advisors LP grew its holdings in BioScrip by 43.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,962,506 shares of the company’s stock worth $5,750,000 after acquiring an additional 597,847 shares during the period. Finally, Benefit Street Partners LLC acquired a new stake in BioScrip during the second quarter worth about $1,053,000. 82.10% of the stock is currently owned by hedge funds and other institutional investors.

BioScrip Company Profile

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

See Also: What are retained earnings?

The Fly

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply